The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
Open accessAbstract
Graft-versus-host disease (GVHD) represents a major hurdle impeding the efficacy of allogeneic bone marrow transplantation (BMT). Bortezomib is a proteasome inhibitor that was recently approved for treatment of myeloma. We found that bortezomib potently inhibited in vitro mixed lymphocyte responses and promoted the apoptosis of alloreactive T cells. Bortezomib given at the time of allogeneic BMT in mice resulted in significant protection from acute GVHD. Reductions in GVHD-associated parameters and biological evidence of proteasome inhibition were observed with this regimen but with no adverse effects on long-term donor reconstitution. Assessment of graft-versus-tumor responses in advanced leukemia-bearing mice demonstrated that only the combination of allogeneic BMT and T cells with bortezomib promoted significant increases in survival. Increased cytotoxic T cell killing of the tumor was also observed. Thus, the combination of proteasome inhibition with selective immune attack can markedly increase the efficacy of BMT in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control · doi:10.1177/107327480301000502 · Cited by 292
Cited by
Garban, F., Attal, M., Michallet, M., Hulin, C., Bourhis, J. H., Yakoub-Agha, I., Lamy, T., Marit, G., Maloisel, F., Berthou, C., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3869 · Cited by 368
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Steen, C. B., Luca, B. A., Esfahani, M. S., Azizi, A., Sworder, B. J., Nabet, B. Y., Kurtz, D. M., Liu, C. L., Khameneh, F., Advani, R. H., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.011 · Cited by 332
Bolaños-Meade, J., Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30221-7 · Cited by 287
Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
Chanan-Khan, A., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9641 · Cited by 263
Metadata
- Authors
- Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S., Blazar, B. R., Sayers, T. J., & Murphy, W. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-05-17
- Volume
- 101
- Issue
- 21
- Pages
- 8120-8125
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2087613277
- Cited by
- 244
- References
- 1
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. https://app.cochat.ai/papers/10.1073/pnas.0401563101
- The paper
- Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S., Blazar, B. R., Sayers, T. J., & Murphy, W. J. (2004). Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0401563101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.